669 Durable responses with triple blockade of the DNAM-1 axis with COM701 + BMS-986207 + nivolumab in patients with platinum resistant ovarian cancer
Main Authors: | Gady Cojocaru, Inbal Barbiro, Amita Patnaik, Manish Sharma, Drew Rasco, Benjamin Izar, Kyriakos P Papadopoulos, Eran Ophir, Ryan Sullivan, Pierre Ferre, Stéphanie Gaillard, Daniel Vaena, Oladapo Yeku, John Moroney, Adeboye H Adewoye |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
29 Immune modulation and baseline biomarker correlation with clinical benefit following treatment with COM701+nivolumab+/-BMS-986207 in patients with platinum resistant ovarian cancer
by: Yu Liang, et al.
Published: (2023-11-01) -
640 The combination of COM701 + nivolumab demonstrates preliminary antitumor activity in patients with metastatic breast cancer
by: Gady Cojocaru, et al.
Published: (2023-11-01) -
Promoting regulation via the inhibition of DNAM-1 after transplantation.
by: Koyama, M, et al.
Published: (2013) -
Preliminary evidence of the association between DNAm and orbital volumetry in GO
by: Ya-Fen Hu, et al.
Published: (2020-07-01) -
Further Introduction of DNA Methylation (DNAm) Arrays in Regular Diagnostics
by: M. M. A. M. Mannens, et al.
Published: (2022-07-01)